UniProt P14081
Selenocysteine-specific elongation factor (P14081)
Selenocysteine-specific elongation factor (UniProt P14081): 5 experimental structures and 1 predicted model on GenesisL1, 3 ligands bound, 6 pockets. Binding sites, druggability and experiment against prediction (TM-score) in…
- UniProt
- P14081
- Protein
- Selenocysteine-specific elongation factor
- Experimental structures
- 5
- Predicted models
- 1
- Ligands
- 3
- Pockets
- 6 · 1 record with a druggable one
Structures
6 records of P14081 in the MolNFT archive: 5 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 2PJP | Structure of the mRNA-binding domain of elongation factor SelB from E.coli in complex with SECIS RNA | x-ray diffraction | A | — | — |
| 2PJP | Structure of the mRNA-binding domain of elongation factor selb from E.COLI in complex with secis RNA | x-ray diffraction | A | — | — |
| 5LZB | Structure of SelB-Sec-tRNASec bound to the 70S ribosome in the initial binding state (IB) | electron microscopy | z | SEC, GNP, MG | — |
| 5LZC | Structure of SelB-Sec-tRNASec bound to the 70S ribosome in the codon reading state (CR) | electron microscopy | z | SEC, GNP, MG | — |
| 5LZD | Structure of SelB-Sec-tRNASec bound to the 70S ribosome in the GTPase activated state (GA) | electron microscopy | z | SEC, MG, GNP | — |
| P14081 | AlphaFold monomer V2.0 prediction for selenocysteine-specific elongation factor (P14081) | predicted | A | — | 6 (best 0.65) |
Ligands
Experiment against prediction
- 2PJP chain A against the predicted model P14081: TM-score 0.95, RMSD 0.92 Å
- 2PJP chain A against the predicted model P14081: TM-score 0.95, RMSD 0.92 Å
- 5LZD chain z against the predicted model P14081: TM-score 0.81, RMSD 3.02 Å
- 5LZB chain z against the predicted model P14081: TM-score 0.79, RMSD 3.51 Å
- 5LZC chain z against the predicted model P14081: TM-score 0.78, RMSD 3.56 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.